The latest progress in assay development in leishmaniasis drug discovery: a review of the available papers on PubMed from the past year

Autor(es)

dos Santos, Gabriela P. ; Coelho, Adriano C. ; Reimao, Juliana Q.

• Tipo de documento: Artigo Científico
• Fonte: EXPERT OPINION ON DRUG DISCOVERY; v. 20, n. 2, p. 16-pg., 2025-01-10.

Resumo

IntroductionLeishmaniasis is a significant neglected tropical disease with limited treatment options that urgently requires ongoing efforts in drug discovery. Recent advances have focused on the development of new assays and methods to identify effective therapeutic candidates.Areas coveredThis review explores recent trends and methodologies in leishmaniasis drug discovery, with a particular focus on in silico and in vitro studies, as well as in vivo validation, using animal models. A detailed analysis of recent studies was provided, discussing the methodologies employed, such as manual and automated parasite quantification, and the use of fluorescence and luminescence-based techniques. Additionally, global research trends were analyzed, highlighting the leading countries in scientific output and the collaborative efforts driving advancements in this field.Expert opinionThe field of leishmaniasis drug discovery has rapidly progressed in the last years, but the lack of standardized methodologies and limited in vivo validation remain significant hurdles. To advance promising treatments to clinical trials, cross-validation of preclinical findings and interdisciplinary collaboration are essential. Increased funding and global partnerships are also crucial to accelerate the discovery and development of alternative and effective therapies. (AU)

• Processo FAPESP: 20/03399-5 - EMU concedido no processo 2018/18954-4: Espectrofluorímetro e Luminômetro de placas
• Beneficiário: Juliana Quero Reimão Dalla Zanna
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 24/15691-3 - Avaliação da atividade anti-Toxoplasma gondii e anti-Leishmania de inibidores de proteases aspárticas
• Beneficiário: Gabriela Pereira dos Santos
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 18/18954-4 - Reposicionamento de fármacos: avaliação de atividade, seletividade e mecanismo de ação de novos candidatos contra Toxoplasma gondii
• Beneficiário: Juliana Quero Reimão Dalla Zanna
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores